newsfilter
← Latest News
GlobeNewswire·

Affimed Reports 2023 Financial Results and Operational Progress

AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer (NSCLC) EGFR-wildtype cohort: one complete response (CR), three partial